2 bargain pharma stocks I’d buy today

Roland Head highlights two pharmaceutical picks you might not have considered.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In October, I warned that it was probably too soon to check back into FTSE 100 pharma group Shire (LSE: SHP). The shares have dropped another 11% since then, rewarding my cautious stand.

However, I still think that Shire has a lot of good qualities. So I’ve taken a fresh look following last week’s final results. Today I’ll explain why I’m now prepared to consider buying.

I’ll also highlight a smaller pharma stock I own that I believe could be a good dividend growth investment.

Strong medicine

In October I flagged up two key risks that were keeping me away from Shire. The first was the challenge of integrating US pharma firm Baxalta, which was acquired for $32bn in 2016.

The second was the group’s net debt of $20.4bn. In my view, this mountain of obligations meant that the stock’s then-P/E ratio of 9.3 wasn’t as cheap as it might have seemed.

Good progress

I’m pleased to report the Dublin-based firm has made good progress in both of these areas. A strong performance from Shire’s Immunology division plus good international growth helped lift product sales by 8% to $14.4bn last year. Adjusted earnings rose by 16% to $15.15 per share. The group’s net profit margin rose by 3% to an impressive 28%.

There was also a worthwhile reduction in debt. Thanks to a 63% increase in free cash flow, net debt fell by $3,370m to $19,069m, despite a $152m rise in capital expenditure.

Although borrowings are still slightly higher than I’d like to see, I believe the speed at which net debt is falling suggests that profit margins could rise steadily over the next couple of years.

With this in mind, I think Shire’s 2018 forecast P/E of 8.4 could be a good level at which to buy for a long-term position.

A specialist growth play

Alliance Pharma (LSE: APH) is a firm you may not have heard of. But this £321m business floated in 2001 and its shares have risen by 750% over the last 10 years.

This specialist company buys up niche medicines and consumer healthcare products. These are then sold through retailers, pharmacies and the group’s own distribution network.

Activities such as manufacturing and warehousing are outsourced to keep capital expenditure to a minimum. The result is that Alliance is very profitable — the Wiltshire-based firm’s operating margin has averaged 28% since 2011.

This business model isn’t without risk. Many of the firm’s products are quite mature. In the future they may be replaced by more effective or cheaper alternatives. Relying on acquisitions for growth is also a risk. A few bad deals could cause profit margins to collapse.

A successful formula

But my assessment of Alliance Pharma’s track record suggests that the firm has found a successful formula and hasn’t tried to diversify too much.

Broker forecasts suggest earnings per share growth of 5% in 2017 and 13% in 2018. A forward dividend yield of 2.1% should be covered three times by earnings, suggesting plenty of scope for dividend growth.

The shares trade on a forecast P/E of 14.9 for 2018, with a PEG ratio of 1.3. I believe attractive gains should be possible from current levels. I continue to hold the shares.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »